Avadel Pharmaceuticals plc Ordinary Share (AVDL) Dividend History

Company News

• Avadel Obtains FDA Nod for Label Expansion Of Narcolepsy Drug Lumryz

  Avadel Pharmaceuticals received FDA approval to expand the label of its narcolepsy drug Lumryz to include treatment of cataplexy or excessive daytime sleepiness in patients aged seven years and older. This expands the drug's indication to the pediatric population and is expected to boost sales.

  Benzinga

  Featured Companies: ALNY ANIP
• Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

  Avadel Pharmaceuticals, a biopharmaceutical company, announced its participation in upcoming investor conferences, including the Wells Fargo Healthcare Conference, Morgan Stanley Global Healthcare Conference, and H.C. Wainwright Global Investment Conference.

  GlobeNewswire Inc.
• Avadel Pharmaceuticals to Join Russell 3000® Index

  DUBLIN, June 27, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024.

  GlobeNewswire Inc.
• Harrow (HROW) Soars 12.9%: Is Further Upside Left in the Stock?

  Harrow (HROW) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

  Zacks Investment Research

  Featured Companies: HROW
• Avadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024

  – 11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefit of LUMRYZ –

  GlobeNewswire Inc.